ResVita Bio Announces RVB-003 granted Orphan Drug Designation for Netherton Syndrome

Date: 04/10/2025

ResVita Bio, a therapeutics company focused on treatments for skin diseases, today announced that the FDA awarded the Orphan Drug Designation to RVB-003 for the treatment of Netherton Syndrome, a chronic and life-threatening skin disorder. Read the press release here https://www.prnewswire.com/news-releases/resvita-bio-announces-rvb-003-granted-orphan-drug-designation-for-netherton-syndrome-by-the-fda-302419290.html

Share This Page:

Are you a new parent?

We have information to help you navigate caring for your child with ichthyosis

Is FIRST in your estate plans?

Let us know so we can say thank you!

Genetic Diagnosis?

Have you received your genetic diagnosis from your doctor?

Double Your Donation to FIRST

Maximize your donation to FIRST with a company match.